|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution’s clinical practice experience显示文摘Background:The antitumour efficacy of tyrosine kinase inhibitors(TKIs)in lung cancer patients with compound epidermal growth factor receptor(EGFR)mutations has not been resolved.Our study summarizes a single institutional experience of first-generation TKI therapy for lung cancers with compound EGFR mutations.Methods:A total of 106 consecutive patients with tumours bearing compound EGFR mutations were identified between January 2012 and May 2016;all patients received first-generation TKI therapy.Deletions in exon 19 and the L858R point mutation in exon 21 were considered common mutations;T790M was considered separately because of its association with TKIs resistances.Any other mutation was defined as a rare mutation.Patients were divided as follows:double common mutations(group A);common plus T790M mutations(group B);common plus rare muta-tions(group C);double rare mutations(group D);and rare plus T790M mutations(group E).A separate group of 115 consecutive patients with a single common mutation was created for comparative analysis(group F).Results:The frequency of patients with compound EGFR was 2.9%(114/3925)and their response rate to first-genera-tion TKIs was 50.9%,which was not significantly different from group F(67.0%,P=0.088).The progression-free survival(PFS)of the 106 patients receiving TKI therapy was worse than that of group F(median,9.1 vs.13.0 months,respec-tively;P<0.001).The PFS of the compound mutation group was shorter than that of the single common mutation group(median,10.1 months in group A,P=0.240;9.1 months in group B,P<0.001;9.6 months in group C,P=0.010;6.5 months in group D,P=0.048;5.4 months in group E,P=0.017).Patients with a co-occurring mutation in exon 20(excluding T790M)exhibited significantly worse PFS than the patients with other compound mutations or with a single common mutation(median,6.5 vs.9.1 vs.13.0 months,respectively,P=0.002).Conclusions:There was significant heterogeneity among the compound EGFR mutations and their response to first-generation TKIs.Individualized treatment in clinical practice should be considered for each case. | Xiangyang Yu Xuewen Zhang Zichen Zhang Yongbin Lin Yingsheng Wen Yongqiang Chen Weidong Wang Lanjun Zhang | 2018 | Cancer Communications2018，38，1： | 5 |
| 2 | The potato amylase inhibitor gene Sb AI regulates cold‐induced sweetening in potato tubers by modulating amylase activity显示文摘 | Huiling Zhang Jun Liu Juan Hou Ying Yao Yuan Lin Yongbin Ou Botao Song Conghua Xie | 2014 | Plant Biotechnol J2014，，7： | 2 |
| 3 | StInvInh2 as an inhibitor of Stvac INV 1 regulates the cold‐induced sweetening of potato tubers by specifically capping vacuolar invertase activity显示文摘 | Xun Liu Yuan Lin Jun Liu Botao Song Yongbin Ou Huiling Zhang Meng Li Conghua Xie | 2013 | Plant Biotechnol J2013，，5： | 2 |
| 4 | The Zα domain of fish PKZ converts DNA hairpin with d(GC)n inserts to Z-conformation显示文摘PKZ,蛋白质 kinase 包含 Z-DNA 领域,是脊椎动物 eIF2 kinase 家庭的一个新奇成员。在 N 终点在 C 终点和二个 Z-DNA 有约束力的领域(Z1 和 Z2 ) 包含一个催化领域, PKZ 能通过 Z 的绑定被激活到 Z-DNA。然而, PKZ Z 的规章的功能尚待被证实。这里,蛋白质被表示在 DNA conformational 转变,野类型的 Z1Z2 和 11 异种上理解 PKZ Z 的影响并且净化。同时, DNA hairpinsd (GC ) 的几不同长度 nT4 (GC ) n (n = 26 ) 并且 RNA hairpinr (GC ) 6T4 (GC ) 6 被综合。这些合成 DNA 或 RNA 发卡的符合构造上的 Z1Z2 和变异的蛋白质的效果被使用圆形的二色性光谱和胶化活动性移动试金调查。结果证明 DNA 发卡当 Z1Z2 不在时保留了常规 B-DNA 符合构造,当一些 DNA 发卡(n3 ) 在 Z1Z2 正式就职下面被变换成 Z 符合构造时。趋势按比例与 GC 重复的增加的数量被联系。与 Z1Z2 比较, Z1Z1 而非 Z2Z2 在变换 d (GC ) 显示了一个更高的能力 6T4 (GC ) 6 从 B- 到 Z-DNA。这些结果证明那 Z1 子域比 Z2 子域在 BZ conformational 转变的过程起了一个更必要的作用。变异的蛋白质(K34A, N38A, R39A, Y42A, P57A, P58A,和 W60A ) 不能变换 d (GC ) 6T4 (GC ) 6 进 Z-DNA,而 S35A 或 K56A 保留了一些部分活动。有趣地, Z1Z2 也能导致 r (GC ) 6T4 (GC ) 从 A 符合构造的 6 RNA 到在适当条件下面的 Z 符合构造。 | Puzhong Lu Shoulong Deng Chuxin Wu Youlin Zhu Yong Liu Gang Lin Yongbin Yan Chengyu Hu | 2013 | Acta Biochimica et Biophysica Sinica2013，45，12： | 2 |
| 5 | Few-shot Named Entity Recognition with Joint Token and Sentence Awareness显示文摘Few-shot learning has been proposed and rapidly emerging as a viable means for completing various tasks.Recently,few-shot models have been used for Named Entity Recognition(NER).Prototypical network shows high efficiency on few-shot NER.However,existing prototypical methods only consider the similarity of tokens in query sets and support sets and ignore the semantic similarity among the sentences which contain these entities.We present a novel model,Few-shot Named Entity Recognition with Joint Token and Sentence Awareness(JTSA),to address the issue.The sentence awareness is introduced to probe the semantic similarity among the sentences.The Token awareness is used to explore the similarity of the tokens.To further improve the robustness and results of the model,we adopt the joint learning scheme on the few-shot NER.Experimental results demonstrate that our model outperforms state-of-the-art models on two standard Fewshot NER datasets. | Wen Wen Yongbin Liu Qiang Lin Chunping Ouyang | 2023 | Data Intelligence2023，5，3： | 1 |
| 6 | E-beam pat- reined gold nanodot arrays on optical fiber tips for localizedsurface plasmon resonance biochemical sensing显示文摘 | Lin Yongbin Zou Yang Mo Yuanyao | 2010 | Sensors2010，10，10： | 1 |
| 7 | Role of Extracellular Signal-Regulated Kinase, p38 Kinase, and Activator Protein-1 in Transforming Growth Factor-β1–Induced Alpha Smooth Muscle Actin Expression in Human Fetal Lung Fibroblasts In Vitro显示文摘 | Yongbin Hu Jinwu Peng Deyun Feng Ling Chu Xiang Li Zhongyuan Jin Zhi Lin Qingfu Zeng | 2006 | Lung2006，，1： | 1 |
| 8 | Mechanochemically conjugated PMHS-nano-SiO2 hybrid and subsequent optimum grafting density study显示文摘 | LIN Jinbin CHEN Honglin YUAN Yongbin | | 0，，21： | 1 |
| 9 | Fish Oil-Supplemented Parenteral Nutrition in Patients Following Esophageal Cancer Surgery: Effect on Inflammation and Immune Function显示文摘 | Hao Long Han Yang Yongbin Lin Dongrong Situ Wanli Liu | 2013 | Nutrition and Cancer2013，，： | 1 |
| 10 | Study of the Modification of Coal-tar Pitch with P-methyl Benzaldehyde显示文摘 | Lin Qilang Li Tiehu Ji Yongbin | 2005 | Fuel2005，84，2： | 1 |
| 11 | Study on the Modification of Coal-tar Pitch with P-methyl Benzaldehyde显示文摘 | Lin Qilang Li Tiehu Ji Yongbin | 2005 | Fuel2005，84，23： | 1 |
| 12 | Taurocholic acid inhibits the response to interferon-αtherapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8^(+)T and NK cell function显示文摘Pegylated interferon-alpha (PegIFNα) therapy has limited effectiveness in hepatitis B e-antigen (HBeAg)-positive chronic hepatitis B (CHB) patients. However, the mechanism underlying this failure is poorly understood. We aimed to investigate the influence of bile acids (BAs), especially taurocholic acid (TCA), on the response to PegIFNα therapy in CHB patients. Here, we used mass spectrometry to determine serum BA profiles in 110 patients with chronic HBV infection and 20 healthy controls (HCs). We found that serum BAs, especially TCA, were significantly elevated in HBeAg-positive CHB patients compared with those in HCs and patients in other phases of chronic HBV infection. Moreover, serum BAs, particularly TCA, inhibited the response to PegIFNα therapy in HBeAg-positive CHB patients. Mechanistically, the expression levels of IFN-γ, TNF-α, granzyme B, and perforin were measured using flow cytometry to assess the effector functions of immune cells in patients with low or high BA levels. We found that BAs reduced the number and proportion and impaired the effector functions of CD3^(+)CD8^(+) T cells and natural killer (NK) cells in HBeAg-positive CHB patients. TCA in particular reduced the frequency and impaired the effector functions of CD3^(+)CD8^(+) T and NK cells in vitro and in vivo and inhibited the immunoregulatory activity of IFN-α in vitro. Thus, our results show that BAs, especially TCA, inhibit the response to PegIFNα therapy by impairing the effector functions of CD3^(+)CD8^(+) T and NK cells in HBeAg-positive CHB patients. Our findings suggest that targeting TCA could be a promising approach for restoring IFN-α responsiveness during CHB treatment. | Zhen Xun Jinpiao Lin Qingqing Yu Can Liu Jinlan Huang Hongyan Shang Jianhui Guo Yuchen Ye Wennan Wu Yongbin Zeng Songhang Wu Siyi Xu Tianbin Chen Jing Chen Qishui Ou | 2021 | Cellular & Molecular Immunology2021，18，2： | 1 |
| 13 | Role of Extracellular Signal-Regulated Kinase, p38 Kinase, and Activator Protein-1 in Transforming Growth Factor-β1–Induced Alpha Smooth Muscle Actin Expression in Human Fetal Lung Fibroblasts In Vitro显示文摘 | Yongbin Hu Jinwu Peng Deyun Feng Ling Chu Xiang Li Zhongyuan Jin Zhi Lin Qingfu Zeng | 2006 | Lung2006，，1： | 1 |
| 14 | 显示文摘 | Lin Qilang Li Tiehu Ji Yongbin | 2005 | Fuel2005，84，23： | 1 |
| 15 | Study of the modification of coal - tar pitch with P - methyl benzaldehyde显示文摘 | Qilang Lin Tiehu Li Yongbin Ji | 2005 | Fuel2005，84，： | 1 |
| 16 | 第一代EGFR酪氨酸激酶抑制剂治疗106例复合EGFR突变肺癌患者:一项单中心临床研究显示文摘背景与目的酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)对具有复合表皮生长因子受体(epidermal growth factor receptor,EGFR)突变的肺癌患者的疗效尚不确切。我们对第一代TKI治疗存在复合EGFR突变肺癌患者的疗效进行了单中心研究。方法2012年1月至2016年5月共确诊106例存在复合EGFR突变的连续肿瘤患者,所有患者均接受第一代TKI治疗。外显子19缺失和外显子21的L858R点突变为常见突变;由于T790M与TKIs耐药性相关,因此单独考虑T790M;其他突变均被定义为罕见突变。患者分组如下:双重常见突变(A组),常见加T790M突变(B组),常见加罕见突变(C组),双重罕见突变(D组)和罕见加T790M突变(E组)。我们建立了一个单独的组(F组),由115例存在单一常见突变的连续患者组成,以进行比较分析。结果EGFR复合突变患者的发生率为2.9%(114/3925),对第一代TKI的反应率为50.9%,与F组相比无显著性差异(67.0%,P=0.088)。接受TKI治疗的106例患者的无进展生存期(progression-free survival,PFS)比F组短(中位数,9.1个月vs.13.0个月,P<0.001)。复合突变组的PFS短于单一常见突变组(中位数,A组10.1个月,P=0.240;B组9.1个月,P<0.001;C组9.6个月,P=0.010;D组6.5个月,P=0.048;E组5.4个月,P=0.017)。外显子20中(不包括T790M)发生共同突变的患者显示出比其他复合突变或单一常见突变患者更短的PFS,差异具有统计学意义(中位数,6.5个月vs.9.1个月vs.13.0个月,P=0.002)。结论复合EGFR突变及其对第一代TKIs的反应存在显著的异质性。在临床中对每位患者都应考虑进行个体化治疗。 | Xiangyang Yu Xuewen Zhang Zichen Zhang Yongbin Lin Yingsheng Wen Yongqiang Chen Weidong Wang Lanjun Zhang | 2019 | 癌症2019，38，10： | 1 |
| 17 | Structural biology investigation of EMF effect on insulin in solution显示文摘It was reported that the a-helix of protein molecules could be destroyed when they were exposed to the electromagnetic field(EMF) and finally the signal transduction could be affected.To study this effect,one signal molecule,insulin,was exposed to electromagnetic fields at different combinations of the field strength,repetition rate and exposure time.For the first time,structural biology approach was used to detect the EMF effect.The results of a series of measurements on the interaction of electromagnetic fields with insulin in vitro are described.Under our experimental conditions,no effects of electromagnetic field exposure were observed on the molecular conformation. | LIU Yahui CHEN Yongbin XU Chunyan XU Shenglong SUN Bo ZHOU Huan SUN Lihua YU Feng TANG Lin GUO Guozhen HE Jianhua | 2011 | Nuclear Science and Techniques2011，22，3： | 0 |
| 18 | Chinese speaker-recognition based on ARMA model显示文摘A Chinese speaker recognition system, which only use speech material of nasal initials and is text-independent, is presented in this paper. According to the properties of speaker’s fixed nasal cavity and stable pharynx cavity when Chinese nasal initials is spoken and a few Chinese nasal initials (the total number of them is only 101 which consists of 53 Tn- and 48 n-), the spectrum parameters of zero and pole point coefficients of all Chinese nasal initials can be gotten by using ARMA model. The performance of this system for 20 speakers is as follows’ The correct recognition rate (CRR) is 87.92% for each speaker to test all initials, when randomly choosing 2, 3, 4 and 5 initials in each speaker’s and then averaging their spectrum to test individual template, the average’ CRRs are 91.67%, 95.00%, 96.67% and 99.97% respectively. | LIN Baocheng CHEN Yongbin(Dept. of Radio Engineering, Southeast University Nanjing 210096) | 1998 | Chinese Journal of Acoustics1998，17，3： | 0 |
| 19 | Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer显示文摘Objective:Real-word data on long-acting luteinizing hormone-releasing hormone(LHRH)agonists in Chinese patients with prostate cancer are limited.This study aimed to determine the real-world effectiveness and safety of the LHRH agonist,goserelin,particularly the long-acting 10.8-mg depot formulation,and the follow-up patterns among Chinese prostate cancer patients.Methods:This was a multicenter,prospective,observational study in hormone treatment-na?ve patients with localized or locally advanced prostate cancer who were prescribed goserelin 10.8-mg depot every 12 weeks or 3.6-mg depot every 4 weeks with or without an anti-androgen.The patients had follow-up evaluations for 26 weeks.The primary outcome was the effectiveness of goserelin in reducing serum testosterone and prostate-specific antigen(PSA)levels.The secondary outcomes included testosterone and PSA levels,attainment of chemical castration(serum testosterone<50 ng/d L),and goserelin safety.The exploratory outcome was the monitoring pattern for serum testosterone and PSA.All analyses were descriptive.Results:Between September 2017 and December 2019,a total of 294 eligible patients received≥1 dose of goserelin;287 patients(97.6%)were treated with goserelin 10.8-mg depot.At week 24±2,the changes from baseline[standard deviation(95%confidence interval)]in serum testosterone(n=99)and PSA(n=131)were-401.0 ng/d L[308.4 ng/d L(-462.5,-339.5 ng/d L)]and-35.4 ng/m L[104.4 ng/m L(-53.5,-17.4 ng/m L)],respectively.Of 112 evaluable patients,100(90.2%)achieved a serum testosterone level<50 ng/d L.Treatment-emergent adverse events(TEAEs)and severe TEAEs occurred in 37.1%and 10.2%of patients,respectively.The mean testing frequency(standard deviation)was 1.6(1.5)for testosterone and 2.2(1.6)for PSA.Conclusions:Goserelin 10.8-mg depot effectively achieved and maintained castration and was well-tolerated in Chinese patients with localized and locally advanced prostate cancer. | Nanhui Chen Zengjun Wang Ming Chen Qi Ma Yi He Yujie Wang Xin Li Mingxing Qiu Lei Shi Shaoxing Zhu Qun Xie Xiuheng Liu Benkang Shi Guowen Lin Weizhong Yang Yongbin Liao Haibin Zhang Shusheng Wang Jiexian Li Shaogang Wang Lijun Dong Hui Chen Jiaju Lu YongyiCheng Xiaoping Zhang Lulin Ma Liqun Zhou He Wang Shen Li Dingwei Ye | 2023 | Cancer Biology & Medicine2023，20，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员